Skip to main content

Table 1 Patient Demographic and Clinical Characteristics

From: Symptoms and impacts in anemia of chronic kidney disease

  Wave 1 CE Interviews (n = 14) Wave 2 Combined CE/CD Interviews (n = 14) Wave 3 CD Interviews (n = 8) All Participants (n = 36)
Age, years, mean ± SD (range) 65 ± 17.6 (30–83) 55 ± 15.8 (32–82) 71.4 ± 14.6 (48–88) 62.7 ± 17.1 (30–88)
Gender, n (%)
 Male 4 (29) 3 (21) 3 (38) 10 (28)
 Female 10 (71) 11 (79) 5 (62) 26 (72)
Race/Ethnicity, n (%)
 White 7 (50) 2 (14) 0 9 (25)
 Black 5 (36) 9 (64) 8 (100) 22 (61)
 Hispanic 2 (14) 3 (21) 0 5 (14)
Education
 Less than HS 0 2 (14) 0 2 (6)
 HS diploma 4 (29) 4 (29) 1 (13) 9 (25)
 Some college 10 (71) 6 (43) 5 (63) 21 (58)
 College degree 0 2 (14) 1 (13) 3 (8)
 Professional or advanced degree 0 0 1 (13) 1 (3)
CKD stage, n (%)
 Stage 3a 1 (7) 0 0 1 (3)
 Stage 3b 2 (14) 1 (7) 3 (38) 6 (17)
 Stage 4 3 (21) 5 (36) 2 (25) 10 (28)
 Stage 5 (not on dialysis) 0 0 2 (25) 2 (6)
 Stage 5 (on dialysis) 8 (57) 8 (57) 1 (13) 17 (47)
Comorbid conditions, n (%)
 Myocardial infarction 1 (7) 2 (14) 0 3 (8)
 Stroke/transient ischemic attack 0 1 (7) 1 (13) 1 (6)
 Arterial hypertension 7 (50) 6 (43) 8 (100) 21 (58)
 Diabetes mellitus 5 (36) 6 (43) 4 (50) 15 (42)
 Cardiovascular disease 1 (7) 0 1 (4) 5 (14)
 Congestive heart failure 2 (14) 7 (50) 2 (25) 11 (31)
 Lung disease 2 (14) 3 (21) 0 5 (14)
Receiving dialysis, n (%)
 Hemodialysis 5 (36) 8 (57) 1 (13) 14 (39)
 Peritoneal dialysis 3 (21) 3 (21) 0 6 (17)
 No 6 (43) 3 (21) 7 (87) 16 (44)
Treatment with ESA, n (%)
 Yes 11 (79) 12 (86) 2 (25) 25 (69)
 No 3 (21) 2 (14) 6 (75) 11 (31)
Hemoglobin, mean ± SD (range, g/dL) 9.8 ± 0.9 (8.7–11.5) 9.5 ± 0.9 (7.2–10.4) 9.1 ± 0.7 (8.0–9.7) 9.5 ± 0.9 (7.2–11.5)
Iron treatment, n (%)
 Intravenous 6 (43) 8 (57) 1 (12) 15 (42)
 Oral 3 (21) 2 (14) 7 (88) 5 (14)
  1. Abbreviations: CD Cognitive debriefing, CE Concept elicitation, CKD Chronic kidney disease, ESA Erythropoietin-stimulating agents, HS High school, SD Standard deviation